Overview

A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

Status:
Not yet recruiting
Trial end date:
2025-01-25
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of HRS9950 tablets in chronic hepatitis B patients who are virologically suppressed on nucleoside or nucleotide analogues (NAs).
Phase:
Phase 2
Details
Lead Sponsor:
Chengdu Suncadia Medicine Co., Ltd.